Pharmaceutical company Mylan received FDA approval of its Abbreviated New Drug Application for Etomidate Injection, a generic anesthesia drug, according to iStockAnalyst.com.
Etomidate Injection is the generic version of Hospira’s Amidate Injection, which is an intravenous general anesthesia.
The newly-approved drug has begun shipping in the United States, and sales for the last 12 months of Etomidate Injection, ending in March, were $6.58M.
More Articles on Anesthesia:
Dr. McCallum R. Hoyt Appointed President of Society for Obstetric Anesthesia and Perinatology
Anesthesiologist Named Chief Medical Officer of Rosellini Scientific
Finding the Right “Fit”: Career Tips for Anesthesia Graduates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
